MX357304B - Formulaciones inmunosupresoras. - Google Patents

Formulaciones inmunosupresoras.

Info

Publication number
MX357304B
MX357304B MX2013007909A MX2013007909A MX357304B MX 357304 B MX357304 B MX 357304B MX 2013007909 A MX2013007909 A MX 2013007909A MX 2013007909 A MX2013007909 A MX 2013007909A MX 357304 B MX357304 B MX 357304B
Authority
MX
Mexico
Prior art keywords
api
immunosuppressant
formulations
compound
immunosuppressant formulations
Prior art date
Application number
MX2013007909A
Other languages
English (en)
Other versions
MX2013007909A (es
Inventor
Bouillot Philippe
Reynaud Emeric
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357304(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013007909A publication Critical patent/MX2013007909A/es
Publication of MX357304B publication Critical patent/MX357304B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica en fase sólida, la cual comprende uno o más excipientes farmacéuticamente aceptables, y un ingrediente farmacéutico activo ("API"), el cual es un compuesto de la fórmula A1 o A2, o una sal, solvato o hidrato farmacológicamente aceptable del mismo, en donde el ingrediente farmacéutico activo (API) no se expone a un compuesto básico.
MX2013007909A 2011-01-07 2012-01-05 Formulaciones inmunosupresoras. MX357304B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150431 2011-01-07
PCT/EP2012/050151 WO2012093161A1 (en) 2011-01-07 2012-01-05 Immunosuppressant formulations

Publications (2)

Publication Number Publication Date
MX2013007909A MX2013007909A (es) 2013-08-29
MX357304B true MX357304B (es) 2018-07-04

Family

ID=44022942

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013007909A MX357304B (es) 2011-01-07 2012-01-05 Formulaciones inmunosupresoras.
MX2017007300A MX371290B (es) 2011-01-07 2012-01-05 Formulaciones inmunosupresoras.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017007300A MX371290B (es) 2011-01-07 2012-01-05 Formulaciones inmunosupresoras.

Country Status (35)

Country Link
US (3) US20130273161A1 (es)
EP (2) EP2661261B1 (es)
JP (2) JP6111202B2 (es)
KR (2) KR102166885B1 (es)
CN (1) CN103458877B (es)
AR (2) AR084801A1 (es)
AU (1) AU2012204835B2 (es)
BR (1) BR112013017302B1 (es)
CA (1) CA2823616C (es)
CL (1) CL2013001979A1 (es)
CO (1) CO6761402A2 (es)
CY (1) CY1122182T1 (es)
DK (1) DK2661261T3 (es)
EA (1) EA026144B9 (es)
EC (1) ECSP13012812A (es)
ES (1) ES2751920T3 (es)
GT (1) GT201300178A (es)
HR (1) HRP20191842T1 (es)
HU (1) HUE045612T2 (es)
IL (1) IL227094B (es)
JO (1) JO3619B1 (es)
LT (1) LT2661261T (es)
MA (1) MA34897B1 (es)
MX (2) MX357304B (es)
MY (1) MY161162A (es)
PE (1) PE20140216A1 (es)
PL (1) PL2661261T3 (es)
PT (1) PT2661261T (es)
SG (1) SG191286A1 (es)
SI (1) SI2661261T1 (es)
TN (1) TN2013000257A1 (es)
TW (2) TWI583380B (es)
UA (1) UA114283C2 (es)
WO (1) WO2012093161A1 (es)
ZA (1) ZA201304465B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943598C (en) * 2014-04-10 2023-03-07 Novartis Ag S1p modulator immediate release dosage regimen
PE20161385A1 (es) * 2014-04-10 2017-01-05 Novartis Ag Formulacion inmunosupresora
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
SI3318259T1 (sl) * 2015-07-03 2023-06-30 Astellas Pharma Inc. Stabilni farmacevtski sestavki za oralno dajanje
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3687498A1 (en) 2017-09-27 2020-08-05 Novartis AG Parenteral formulation comprising siponimod
AU2018343239A1 (en) 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
US20200316021A1 (en) 2017-09-29 2020-10-08 Novartis Ag Dosing Regimen of Siponimod
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021214717A1 (en) 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
WO2023172508A1 (en) * 2022-03-09 2023-09-14 Isp Investments Llc Co-processed excipient composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225964B1 (en) 1994-07-12 2008-01-28 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
ATE527986T1 (de) * 2002-11-07 2011-10-15 Taisho Pharmaceutical Co Ltd Grundlage für orale zusammensetzung und orale zusammensetzung
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
EP3120833A1 (en) * 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
ES2526119T3 (es) 2008-08-18 2015-01-07 Novartis Ag Derivado de azetidina para el tratamiento de neuropatías periféricas
PE20120336A1 (es) * 2008-12-18 2012-04-30 Novartis Ag Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-triflouro-metil-benciloxi-imino)-etil)-2-etil-bencil]-azetidin-3-carboxilico
AU2009335887A1 (en) 2008-12-18 2011-06-30 Novartis Ag New salts
BRPI0922457A2 (pt) 2008-12-18 2015-12-15 Novartis Ag forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
KR101660555B1 (ko) 2008-12-22 2016-09-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 요법

Also Published As

Publication number Publication date
EA201391018A1 (ru) 2013-11-29
CA2823616A1 (en) 2012-07-12
ECSP13012812A (es) 2013-09-30
TWI583380B (zh) 2017-05-21
TW201609092A (zh) 2016-03-16
HRP20191842T1 (hr) 2019-12-27
UA114283C2 (uk) 2017-05-25
CN103458877B (zh) 2016-06-08
BR112013017302A2 (pt) 2016-10-25
MX2013007909A (es) 2013-08-29
PL2661261T3 (pl) 2020-01-31
ES2751920T3 (es) 2020-04-02
LT2661261T (lt) 2019-10-25
KR102166885B1 (ko) 2020-10-19
MX371290B (es) 2020-01-24
CY1122182T1 (el) 2020-11-25
ZA201304465B (en) 2014-02-26
AU2012204835A1 (en) 2013-08-01
TWI610672B (zh) 2018-01-11
AR124662A2 (es) 2023-04-19
NZ612420A (en) 2015-05-29
US20130273161A1 (en) 2013-10-17
TW201249438A (en) 2012-12-16
SG191286A1 (en) 2013-07-31
GT201300178A (es) 2014-12-30
CN103458877A (zh) 2013-12-18
JP6111202B2 (ja) 2017-04-05
EP2661261A1 (en) 2013-11-13
TN2013000257A1 (en) 2014-11-10
AU2012204835B2 (en) 2015-07-09
EP3590507A1 (en) 2020-01-08
CA2823616C (en) 2019-01-29
US20200199069A1 (en) 2020-06-25
IL227094B (en) 2019-03-31
JP2014501770A (ja) 2014-01-23
JP2017141248A (ja) 2017-08-17
KR101951966B1 (ko) 2019-02-25
KR20140037815A (ko) 2014-03-27
EA026144B1 (ru) 2017-03-31
JP6324569B2 (ja) 2018-05-16
MY161162A (en) 2017-04-14
BR112013017302B1 (pt) 2021-12-07
KR20190025727A (ko) 2019-03-11
WO2012093161A1 (en) 2012-07-12
EA026144B9 (ru) 2021-10-26
HUE045612T2 (hu) 2020-01-28
PT2661261T (pt) 2019-10-25
US20220064110A1 (en) 2022-03-03
JO3619B1 (ar) 2020-08-27
PE20140216A1 (es) 2014-03-01
MA34897B1 (fr) 2014-02-01
EP2661261B1 (en) 2019-07-31
SI2661261T1 (sl) 2019-11-29
AR084801A1 (es) 2013-06-26
DK2661261T3 (da) 2019-10-21
CL2013001979A1 (es) 2013-11-22
CO6761402A2 (es) 2013-09-30

Similar Documents

Publication Publication Date Title
TN2013000257A1 (en) Immunosuppressant formulations
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
MY187718A (en) Pharmaceutical formulations
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EA201692298A1 (ru) Производные карбоксамидов
PH12015501386A1 (en) Tricyclic compounds
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
TN2014000060A1 (en) Benzothiazolone compound
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
TN2012000568A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.
TN2012000617A1 (en) 2,3,5-trisubstituted thiophene compounds and uses thereof
PH12016502247A1 (en) Carboxamide derivatives

Legal Events

Date Code Title Description
FG Grant or registration